皮质类固醇对COVID-19后气味丧失的影响:一个元分析
Mona Kabiri1, Maryam Emadzadeh2
1Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Iranian journal of otorhinolaryngology
|December 13, 2023
概括
皮质类固醇可能有助于患者从COVID-19相关的嗅觉丧失 (无臭症) 中恢复. 较长的治疗持续时间,超过两周,似乎最有效地改善嗅觉功能和恢复率.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- COVID-19经常导致嗅觉功能障碍,包括厌氧 (嗅觉丧失),影响了很大比例的患者.
- 目前,没有确定的治疗方法被批准用于COVID-19后的无氧化.
- 本综述研究了皮质类固醇在COVID-19感染后治疗嗅觉功能障碍时的疗效.
研究的目的:
- 系统地审查随机对照试验,评估COVID-19后阳/阴的皮质类固醇治疗.
- 评估皮质类固醇对COVID-19患者嗅觉恢复的持续时间和质量的影响.
主要方法:
- 在主要的科学数据库 (PubMed,科学网,Scopus,Cochrane图书馆) 进行了系统的搜索,直到2022年9月.
- 包括的研究是以英语出版的随机对照试验,重点是针对COVID-19后嗅觉功能障碍的皮质类固醇.
- 分析了6项涉及712名参与者的试验数据,将干预组 (皮质类固醇) 与对照组进行比较.
主要成果:
- 虽然没有发现嗅觉改善的持续时间有显著差异,但客观评估显示,干预组在治疗终点时的嗅觉得分更高.
- 在接受皮质类固醇治疗的患者中,聚合分析表明,接受皮质类固醇治疗的患者在厌氧后的康复率更高 (几率比: 1.719).
- 自我评价的嗅觉得分在两周或研究终点时没有显著改善,但客观测量表明有好处.
结论:
- 皮质类固醇治疗在改善嗅觉功能的客观测量和增加COVID-19后无氧化症患者的康复率方面表现有前途.
- 超过两周的治疗时间对于从嗅觉功能障碍中获得相当大的恢复可能至关重要.
- 对COVID-19后嗅觉损失的最佳皮质类固醇疗法进行进一步的研究是有必要的.
更多相关视频
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
4.8K
06:29Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
2.4K
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
213
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
213
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
266
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
266
01:17Drugs Used in Lower Respiratory Disorders: Overview
450
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
450